Novo Nordisk increases 2023 sales, profit outlook as semaglutide sales boom
Novo Nordisk announced substantial first-quarter sales growth for two of its three semaglutide products, Ozempic and Wegovy, and is raising its full-year revenue and profit outlook based on their strength.
First-quarter sales were up 25%, the Danish drugmaker announced Thursday, compared with 42.03 billion Danish kroner, or roughly $6.2 billion, a year ago. Quarterly operating profit was up 28%, the company said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.